Legal Representation
Attorney
Gregory B. Phillips
USPTO Deadlines
Next Deadline
1988 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-12-31)
Due Date
December 31, 2030
Grace Period Ends
June 30, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
17 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 31, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Dec 31, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Nov 12, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 12, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 23, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 3, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 3, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Oct 3, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 3, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 3, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 19, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 19, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 19, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 5, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 28, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 19, 2024 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Jan 9, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of cancer, auto-immune diseases and infectious diseases; pharmaceutical preparations containing antibodies for the treatment of cancer, auto-immune diseases and infectious diseases; pharmaceutical preparations containing recombinant proteins for the treatment of cancer, auto-immune diseases and infectious diseases
Classification
International Classes
005